NICE says no to Xalkori; appeal is 'pointless' says Pfizer
This article was originally published in Scrip
Despite the offer of a price discount, Pfizer has failed to convince NICE, the health technology appraisal institute for England and Wales, to recommend its lung cancer drug Xalkori (crizotinib). NICE says the drug is not cost-effective and has doubts over its overall survival benefits.
You may also be interested in...
While information sharing is key to cross-country collaborations on access to medicines and can lead to major benefits, it is hard to sell to political leaders and the media, says a report from the World Health Organization’s regional office for Europe.
The European Commission says it will publish its review of the EU orphan drug legislation in the coming days.
The UK has formally withdrawn its ratification of the Unified Patent Court Agreement, adding to the uncertainty over its future.